Harte Steven E, Kender Robert G, Borszcz George S
Department of Psychology, Behavioral and Cognitive Neuroscience Program, Wayne State University, 71 W. Warren Ave., Detroit, MI 48202, USA.
Pain. 2005 Feb;113(3):405-415. doi: 10.1016/j.pain.2004.11.023.
The antinociceptive effects of the serotonin (5-HT)1A/7 receptor agonist 8-hydroxy-dipropylaminotetralin (8-OH-DPAT) administered into the medial thalamus were evaluated. Pain behaviors organized at spinal (spinal motor reflexes, SMRs), medullary (vocalizations during shock, VDSs), and forebrain (vocalization after discharges, VADs) levels of the neuraxis were elicited by tailshock. Administration of 8-OH-DPAT (5, 10, and 20 microg/side) into nucleus parafascicularis (nPf) produced dose-dependent increases in VDS and VAD thresholds, but failed to elevate SMR threshold. The increase in VAD threshold was significantly greater than that of VDS threshold. Similar effects were observed with administration of 8-OH-DPAT (20 microg/side) into the rostral portion of the central lateral thalamic nucleus. The bilateral or unilateral administration of 8-OH-DPAT (20 microg) into other thalamic nuclei, or into sites dorsal to nPf, did not elevate vocalization thresholds. Increases in vocalization thresholds produced by nPf-administered 8-OH-DPAT were mediated by both 5-HT1A and 5-HT7 receptors. Intra-nPf administration of the 5-HT1A receptor antagonist WAY-100635 (0.05 or 0.5 microg/side), or the 5-HT7 receptor antagonist SB-269970 (1 or 2 microg/side), but not the dopamine D2 receptor antagonist raclopride (10 microg/side), reversed 8-OH-DPAT induced elevations in vocalization thresholds. These results provide the first reported evidence of behavioral antinociception following the administration of a 5-HT agonist into the medial thalamus.
评估了向内侧丘脑注射5-羟色胺(5-HT)1A/7受体激动剂8-羟基二丙基氨基四氢萘(8-OH-DPAT)的抗伤害感受作用。通过尾部电击引发在神经轴的脊髓(脊髓运动反射,SMR)、延髓(电击时发声,VDS)和前脑(放电后发声,VAD)水平上组织的疼痛行为。向束旁核(nPf)注射8-OH-DPAT(5、10和20微克/侧)会使VDS和VAD阈值呈剂量依赖性增加,但未能提高SMR阈值。VAD阈值的增加明显大于VDS阈值的增加。向丘脑中央外侧核的嘴侧部分注射8-OH-DPAT(20微克/侧)也观察到类似效果。向其他丘脑核或nPf背侧部位双侧或单侧注射8-OH-DPAT(20微克)不会提高发声阈值。nPf注射8-OH-DPAT所产生的发声阈值增加是由5-HT1A和5-HT7受体介导的。向nPf内注射5-HT1A受体拮抗剂WAY-100635(0.05或0.5微克/侧)或5-HT7受体拮抗剂SB-269970(1或2微克/侧),但不是多巴胺D2受体拮抗剂雷氯必利(10微克/侧),可逆转8-OH-DPAT诱导的发声阈值升高。这些结果提供了首次报道的向内侧丘脑注射5-HT激动剂后行为性抗伤害感受的证据。